3Tsuge M, Yasui K, Ichiyawa T, et al. increase of tumor necrosis factor-alpha in the blood induces early activation of matrix metalloproteinase-9 in the brain. Microbiol Immunol, 2010, 54: 417-424.
4Vilaha A, Sahuquillo J, Poca MA, et al. Brain contusions induce a strong local overexpression of MMP-9. Results of a pilot study. Acta Neuruchir Suppl, 2008, 102 : 415-419.
5Nicot A. Gender and sex hormones in multiple sclerosis pathology and therapy. Front Biosci, 2009, 14: 4477-4515.
6Niino M, Hirotani M, Fukazawa T, et al. Estrogens as potential therapeutic agents in multiple sclerosis. Cent Nerv Syst Agents Med Chem, 2009, 9: 87-94.
7Soldan SS, Alvarez Retuerto AI, Sicotte NL, et al. Immune modulation in multiple sclerosis patients treated with the pregnancy hormone cstriol. J Innnunol, 2003, 171 : 6267-6274.
8Suzuki S, Brown CM, Dela Cruz CD, et al. Timing of estrogen therapy after ovariectomy dictates the efficacy of its neuroproteetive and antiinflammatnry actions. Prnc Natl Acad Sci U S A, 2007, 104 : 6013-6018.
9Garay L, Gonzalez Deniselle MC, Gierman L, et al. Steroid proteetion in the experimental autoimmune encephalomyelitis model of multiple sclerosis. Neuroimmunomodulation, 2008, 15 : 76-83.
10Gold SM, Sasidhar MV, Morales LB, et al. Estrogen treatment decreases matrix metalloproteinase (MMP)-9 in autoinnnune demyellnating disease through estrogen receptor alpha (ERalpha). Lab Invest, 2009, 89 : 1076-1083.
